SDDS 2021

Stanford Drug Discovery Symposium

April 19-20, 2021

WELCOME & REGISTRATION

Welcome to the 2021 Stanford Drug Discovery Symposium

The Stanford Drug Discovery Symposium is an exciting forum to hear about drug discovery from leaders in the field. Speakers include leaders at major pharmaceutical companies, biotech industry, federal policy makers, venture capital firms, editors from major publications, and scientists making groundbreaking advances. The meeting also provides perspectives into how COVID-19 has led to change in these landscapes. We look forward to your participation in this exciting event.

REGISTRATION

https://tinyurl.com/SDDS2021

DAY-OF VIEWING PAGE

https://tinyurl.com/sdds2021-livestream

SOCIAL MEDIA

#SDDS2021

Participant Interaction Platform

SDDS will be using **Slido** as a platform to send questions to the speakers. Please note that the speakers may not have time to answer all questions during the panel sessions.

Slido is accessible using the following formats:

Webpage: Simply type your question in the Slido interface to the right of the video box on the viewing webpage.

New browser window: Open the Slido website in a new browser window and enter participant code **#SDDS2021** in the "Joining as a Participant" field at the top of the page.

Cellphone: You can use Slido on your mobile phone (no app download required). Just scan the QR code to the right.

SCHEDULE - MONDAY, APRIL 19

Time (PDT)

WELCOME TO DAY 1

9:00 am **Joseph Wu, MD, PhD**
Director, Stanford Cardiovascular Institute

9:05 am **Marc Tessier-Lavigne, PhD**
President, Stanford University

9:10 am **Lloyd Minor, MD**
Dean, Stanford School of Medicine

SESSION I: BIOLOGY OF DISEASE

Moderators: Helen Blau, PhD, and Mark Mercola, PhD

9:15 am **Brian Kobilka, MD**
Helene Irwin Fagan Chair in Cardiology, Stanford University; Nobel prize in 2012
Challenges in Drug Discovery for G Protein Coupled Receptors

9:35 am **Roger Kornberg, PhD**
Mrs. George A. Winzer Professor in Medicine, Stanford University; Nobel prize in 2006
New Paradigms in Drug Discovery

9:49 pm **Peter Kim, PhD**
Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University
Toward a Single-dose, Room-temperature Stable COVID-19 Vaccine

10:03 am Panel Discussion

10:25 am Break

SESSION II: INVESTING IN DISCOVERY

Moderators: Nina Kjellson and Kuldev Singh, MD

10:40 am **Young Sohn, MS**
Chairman of the Board, HARMAN and Senior Advisor, Samsung Electronics
The Data Journey of the Voice of the Body

10:53 am **Jürgen Eckhardt, MD**
Head of Leaps by Bayer
Breaking through Impossible

11:03 am **Carmen Chang, MA, JD**
General Partner; Head of Asia, New Enterprise Associates
Venture and Growth Technology and Healthcare at Scale

11:13 am **Nanna Lüneborg, PhD, MBA**
Partner, Novo Ventures
Venture Investment in Drug Discovery - A European Perspective

11:23 am Panel Discussion

Time (PDT) **SESSION III: DISCOVERY RESEARCH I**
Moderator: Sandra Horning, MD, and Sanjay Malhotra, PhD

11:45 am **Taiyin Yang, PhD**
Executive Vice President, Pharmaceutical Development and Manufacturing, Gilead
Making Medicines – A Partnership

12:02 pm **Stanley T. Crooke, MD, PhD**
Ionis Pharmaceuticals Executive Chairman of the Board
RNA Targeted Drug Discovery: From Pipe Dream to Reality

12:20 pm **Marcus Schindler, PhD**
Executive Vice President and CSO of Research & Early Development, Novo Nordisk
Re-defining the Novo Nordisk Approach to Drug Discovery

12:33 pm **Hal Barron, MD**
CSO and President, GlaxoSmithKline
Human Genetics, Functional Genomics and AI/ML in Drug Discovery

12:51 pm **Wendy Young, PhD**
Senior Vice President, Small Molecule Drug Discovery, Genentech
Drug Discovery: Where are We Headed?

1:07 pm Panel Discussion

1:30 pm Break

SESSION IV: DISSEMINATING DRUG DISCOVERY FINDINGS

Moderators: Amanda Chase, PhD, and Mark Mercola, PhD

1:45 pm Panel Discussion Featuring:
Michael Basson, PhD, Senior Editor, Nature Medicine
Orla Smith, PhD, Editor, Science Translational Medicine
Michael Nedelman, CNN Producer

Time (PDT)

SESSION V: LIFETIME ACHIEVEMENT AWARD PRESENTATION

Moderator: Philip Pizzo, MD

2:10 pm **I**ntroduction of Douglas R. Lowy, MD, and John T. Schiller, PhD
Philip Pizzo, MD
David and Susan Heckerman Professor and Professor of Microbiology and Immunology, Stanford University

2:15 pm Awardee Lecture: **Douglas R. Lowy, MD**
Principal Deputy Director, National Cancer Institute
Virus-like Particle Vaccination for Preventing HPV-Associated Cancers

2:35 pm Awardee Lecture: **John T. Schiller, PhD**
Deputy Chief, Laboratory of Cellular Oncology
Moving Beyond Personalized Therapies for Cancer

2:55 pm Q&A Session

3:10 pm Day 1 Closing Remarks
Joseph Wu, MD, PhD

SCHEDULE - TUESDAY, APRIL 20

Time (PDT)

WELCOME TO DAY 2

9:00 am **Joseph Wu, MD, PhD**
Director, Stanford Cardiovascular Institute
Simon H. Stertzer, MD, Professor of Medicine and Radiology
Stanford University

SESSION VI: COVID-19 INDUSTRY AND SOCIETAL SHIFTS

Moderators: Andrew Plump, MD, PhD, and Julie Parsonnet, MD

9:05 am **Janet Woodcock, MD**
Acting Commissioner, FDA
The Clinical Trial Enterprise: Lessons from a Pandemic

9:27 am **Kathrin Jansen, PhD**
Senior Vice President, Head of Vaccine Research and Development, Pfizer
Learnings from the Development of the BNT162b2 mRNA COVID-19 Vaccine

9:41 am **Anne Heatherington, PhD**
Senior Vice President, Head of Data Sciences Institute, Takeda
COVID-19: It's the End of the World as We Know it…

9:50 am **Andrea Carfi, PhD**
Vice President and Head of Research, Infectious Disease, Moderna, Inc.
Development of the Moderna COVID-19 Vaccine (mRNA-1273)

10:00 am Panel Discussion featuring:
Janet Woodcock, MD; Kathrin Jansen, PhD; Anne Heatherington, PhD; Mathai Mammen, MD, PhD; Yvonne Maldonado, MD; Andrea Carfi, PhD

10:25 am Break

SESSION VII: STANFORD DRUG DISCOVERY SHOWCASE

Moderators: Camille Samuels, MBA, and Sanjay Malhotra, PhD

10:40 am **Fady Malik, MD, PhD**
Executive Vice President, Research and Development, Cytokinetics
The Cardiac Myosin Activator, Omecamtiv Mecarbil: From Concept to Clinic

10:50 am **Serge Saxonov, PhD**
Co-Founder and CEO, 10X Genomics
Mastering Biology to Advance Human Health

11:02 am **Mir Imran, MS**
Chairman and CEO, Rani Therapeutics

11:12 am **Ken Mills**
President and CEO, REGENXBIO
A Brief, Recent History of Drug Discovery in AAV Gene Therapy

11:20 am Panel Discussion

SCHEDULE - TUESDAY, APRIL 20

Time (PDT)

SESSION VIII: DISCOVERY RESEARCH II

Moderators: Marc Tessier-Lavigne, PhD, and Kuldev Singh, MD

11:45 am **George Yancopoulos, MD, PhD**
President & CSO, Regeneron
The VelociSuite Platform for COVID-19 Antiviral Therapy

12:01 pm **Joan Mannick, MD**
Head of Research and Development, Life Biosciences
Targeting the Biology of Aging to Prevent or Treat Aging-related Diseases

12:17 pm **Mathai Mammen, MD, PhD**
Global Head of Research and Development,
Janssen Pharmaceutical, Johnson & Johnson
Creating Transformational Medicines

12:33 pm **Levi Garraway, MD, PhD**
CMO, Genentech
Towards Personalized Healthcare in Therapeutic Development

12:48 pm **Thomas Hudson, MD**
Senior Vice President, R&D and Chief Scientific Officer, AbbVie
Data Convergence and Innovation Medicine

1:00 pm Panel Discussion

1:25 pm Break

SESSION IX: HEALTH POLICY

Moderators: Lloyd Minor, MD, and Woodrow A. Myers, Jr., MD, MBA

1:40 pm **Helene Gayle, MD, MPH**
President & CEO, The Chicago Community Trust
Fireside chat with Woodrow A. Myers, Jr., MD, MBA

1:53 pm **Mark Smith, MD, MBA**
Founding President & CEO, California Healthcare Foundation
Disruptive Innovation in Health Care: In Memory of Clayton Christensen

2:06 pm **Elias Zerhouni, MD**
Former President for R&D, Sanofi; former Director of the NIH; former U.S. Presidential Science Envoy
Drug Discovery and Bioinnovation: Opportunities and Challenges

2:24 pm **Robert Califf, MD**
Head of Strategy and Policy, Verily Life Sciences and Google Health Divisions of Alphabet
The Post-COVID Crisis in CV Disease – Policy Implications

2:40 pm Panel Discussion

3:00 pm Closing Remarks

LIFETIME ACHIEVEMENT AWARDEES



Douglas R. Lowy, MD

Dr. Lowy is the Principal Deputy Director of the National Cancer Institute (NCI), National Institutes of Health (NIH). He is also Chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI. He received his medical degree from New York University School of Medicine and trained in internal medicine at Stanford University and dermatology at Yale. He has been the NCI Principal Deputy Director since 2010, was the Acting Director 2015-2017, and resumed this role again for seven months in 2019. Dr. Lowy's research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. His papillomavirus research is carried out in close collaboration with Dr. John Schiller, with whom he has co-authored more than 150 papers over the past 30 years. In the 1980s, they studied the genetic organization of papillomaviruses and identified the oncogenes encoded by the virus. Starting in the 1990's, they focused on papillomavirus vaccines and the papillomavirus life cycle. Their laboratory was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three FDA-approved HPV vaccines. In response to the COVID-19 pandemic, he has led the SARS-CoV-2 serology research effort at NCI. Dr. Lowy is a member of the National Academy of Sciences (NAS) and of the Institute of Medicine of the NAS. For their HPV vaccine research, he and Dr. Schiller have received numerous honors, including the 2007 Federal Employee of the year Service to America Medal from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, the 2012 National Medal of Technology & Innovation (awarded in 2014), and the 2017 Lasker-DeBakey Clinical Medical Research Award. Dr. Lowy has also received the National Medal of Honor for Basic Research from the American Cancer Society and the Science of Oncology Award from the American Society for Clinical Oncology.

John T. Schiller, PhD

Dr. Schiller graduated from the University of Wisconsin-Madison with a BS in molecular biology in 1975. In 1982, he received a PhD from the Department of Microbiology of the University of Washington in Seattle, then joined the Laboratory of Cellular Oncology as a National Research Service Award postdoctoral fellow in 1983. Dr. Schiller became a senior staff fellow in the Laboratory of Cellular Oncology in 1986 and a senior investigator in 1992. He became chief of the Neoplastic Disease Section of the lab in 1998, deputy lab chief in 2000, and designated as an NIH Distinguished Investigator in 2016. Dr. Schiller has received numerous awards for his contributions to papillomavirus virus molecular biology and HPV vaccine development, including the 2007 Federal Employee of the year Service to America Medal from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, the 2011 AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention, the 2014 National Medal of Technology and Innovation, the 2017 American Society for Microbiology's Joseph Public Health Award, and the 2017 Lasker-DeBakey Clinical Medical Research Award.

PARTICIPANTS

Hal Barron, MD

Hal V. Barron, MD, joined GSK as Chief Scientific Officer and President, Research and Development in January 2018. His previous role was President, R&D at Calico (an Alphabet-backed life sciences company). Prior to this, Dr. Barron was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer. Dr. Barron was previously a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc. He is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. Dr. Barron holds a BS degree in Physics from Washington University in St. Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.

Michael Basson, PhD

As a graduate student in Jasper Rine's laboratory at University of California at Berkeley, Dr. Basson studied the sterol biosynthetic pathway and its rate-limiting enzyme HMG-CoA reductase in baker's yeast. His postdoctoral work was on developmental genetics and microRNAs with Robert Horvitz at the Massachusetts Institute of Technology. He then worked in the biotech industry, first on the use of model organisms for drug discovery and then on tumor angiogenesis. Dr. Basson is currently Senior Editor at Nature Medicine, and handles research manuscripts in the fields of cardiovascular disease & hematology, precision medicine & big data, and bioengineering & biotechnology. He joined Nature Medicine in 2003.

Helen Blau, PhD

Dr. Blau is The Donald E. and Delia B. Baxter Foundation Professor; Director, Baxter Laboratory for Stem Cell Biology; and Professor, by courtesy, of Psychiatry and Behavioral Sciences. Her research area is stem cell biology, aging, and regenerative medicine. She is world renowned for her work on nuclear reprogramming and demonstration of the plasticity of cell fate using cell fusion. Dr. Blau's lab made the unexpected finding that short telomeres are a hallmark of genetic dilated cardiomyopathies and constitute premature aging disorders. Her lab also identified biomaterials and molecular regulators that synergize to rejuvenate aged muscle stem cell function, augmenting strength. From these studies, new therapeutic paradigms have emerged for cardiac and skeletal muscle disorders.

PARTICIPANTS

Robert M. Califf, MD

Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health. Prior to this, Dr. Califf was the Vice Chancellor for Health Data Science for the Duke University School of Medicine; Director of Duke Forge, Duke's Center for Health Data Science; and the Donald F. Fortin, MD, Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.

Andrea Carfi, PhD

Dr. Carfi is the Vice President and Head of Research, Infectious Disease at Moderna. After receiving his doctorate under the direction of Otto Dideberg (retired) at the Institut de Biologie Structurale (IBS) in 1997 he completed his training as a postdoctoral fellow in Prof. Don Wiley's group at Children's Hospital (Harvard University) in Boston, MA. Andrea Carfi then moved to industry, joining Merck in 2002. He returned to Cambridge (USA) in 2010 as a senior manager first at Novartis Vaccines and then GSK vaccines. He joined Moderna in 2017, where he contributed to the development of Moderna's COVID-19 mRNA vaccine that was recently approved for use by the European Medicines Agency.

Carmen Chang, MA, JD

Carmen Chang joined New Enterprise Associates (NEA) in 2012 and serves as a General Partner and Chairman and Head, Asia. In this role, she is focused on building NEA's global organization and portfolio in China and other emerging markets in Asia. Ms. Chang serves on the board of directors of Woebot, a unique artificial intelligence based digital mental health company, Tuya, a one-stop IOT solutions platform for device manufacturers, STX Entertainment, a fully integrated global media company, Moqi, an innovative player in biometrics identification, Cista, a developer of image sensor systems, Availink, Alien Technology, and Simple Psychology, an online discovery engine for psychotherapy; she also works closely with Bytedance and Zuoyebang. Prior to joining NEA, Ms. Chang was a partner at a major Silicon Valley law firm, where she specialized in corporate and securities law and led that firm's China practice. She has been involved with many of the seminal technology transactions and companies in China, including the first foreign investments in China Netcom; companies such as Lenovo, Foxconn, Google, Tencent, Netease, CEC, China Mobile and others; the IPOs of SMIC, Spreadtrum, and others; and numerous acquisitions and mergers. In addition to her role with NEA, Carmen is a fellow for the Rock Center for Corporate Governance at Stanford University and holds a MA degree in Modern Chinese History from Stanford University and a JD from Stanford Law School.

PARTICIPANTS



Stanley T. Crooke, MD, PhD

Dr. Crooke is the founder and former Chief Executive Officer of Ionis Pharmaceuticals. In 2020, Dr. Crooke assumed the Executive Chairman role at Ionis Pharmaceuticals, continuing to lead research into the molecular mechanisms of antisense oligonucleotides and lead n-Lorem, a charitable foundation he has founded to create and supply antisense oligonucleotide medicines for patients with ultra-rare diseases. During his tenure at Ionis, he has led the scientific development of a new platform for drug discovery, antisense technology and engineered the creation of one of the largest and more advanced development pipelines in the biotechnology industry. Early in Dr. Crooke's career, he led the creation of the first broad anticancer program in the industry at Bristol-Myers, bringing numerous anticancer drugs to the market in the first five years of his career. He then assumed responsibility for worldwide R&D at SmithKline Beckman. Dr. Crooke has received a number of awards, most recently, the American Chemical Society's E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Lifetime Achievement Award presented by the Oligonucleotide Therapeutics Society, the Scrip Lifetime Achievement Award, and the 2019 Massry Prize. Dr. Crooke received his MD and PhD degrees and house staff training at Baylor College of Medicine and has been an active scientist throughout his career. He has published more than 500 scientific publications, edited more than 20 books, has numerous patents, and led the development of more than 23 drugs that have been commercialized.

Jürgen Eckhardt, MD

Dr. Eckhardt is SVP and Head of Leaps by Bayer, the impact investment unit of Bayer. The mission of Leaps is to invest in breakthrough technologies and disruptive business models in the areas of healthcare and agriculture. Dr. Eckhardt has been a venture investor since 2002 and currently serves on the boards of Joyn Bio, Dewpoint, Century, Khloris, Oerth Bio, Immunitas, eGenesis, and others. Previously, Jürgen was a management consultant and Associate Partner with McKinsey & Co. and a member of McKinsey's Healthcare Leadership Team. He began his career as a radiologist at the University Hospital of Basel, Switzerland. Jürgen received his MD from the University of Basel and his MBA from INSEAD in Fontainebleau, France.

Levi Garraway, MD, PhD

Dr. Garraway, MD, PhD, was appointed Chief Medical Officer and Executive Vice President, Head of Global Product Development for Roche Genentech in October 2019. He leads employees in the Product Development organization across the globe, oversees all aspects of late stage clinical development, and co-chairs the Late Stage Portfolio Committee that invests in pivotal registrational trials. Prior to joining Roche, Levi served as Senior Vice President, Oncology Research and Development and Novel Target Research at Eli Lilly and Company. He also served as an investigator of the Howard Hughes Medical Institute and an Associate Professor of Medicine at the Dana-Farber Cancer Institute, Harvard Medical School, and an Institute Member of the Broad Institute. Levi was the inaugural Director of the Joint Center for Cancer Precision Medicine, which spans several top research institutions including Dana-Farber Cancer Institute, Boston Children's Hospital, and the Broad Institute. Levi led a research group that studied cancer genomics and drug resistance, developing a platform for systematic cancer mutation profiling that inspired multiple personalized cancer medicine efforts across the U.S. and beyond. Levi has received numerous awards including the Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from American Association for Cancer Research, the New Innovator Award from the National Institutes of Health (NIH), and an Outstanding Investigator Award from the National Cancer Institute (NCI). In 2009, Levi was inducted into the American Society for Clinical Investigation and served as its President from 2015-16. In 2015, he was inducted into the Association for American Physicians. Levi received his Bachelor of Arts, Doctor of Medicine and Philosophy degrees from Harvard Medical School. He completed post-doctoral training in internal medicine at the Massachusetts General Hospital and fellowship training in medical oncology at the Dana-Farber Cancer Institute.

Helene Gayle, MD, MPH

Helene D. Gayle has been president and CEO of The Chicago Community Trust, one of the nation's oldest and largest community foundations, since October 2017. Under her leadership, the Trust has adopted a new strategic focus on closing the racial and ethnic wealth gap in the Chicago region. For almost a decade, she was President and CEO of CARE, a leading international humanitarian organization. An expert on global development, humanitarian, and health issues, Dr. Gayle spent 20 years with the Centers for Disease Control, working primarily on HIV/AIDS. She worked at the Bill & Melinda Gates Foundation, directing programs on HIV/AIDS and other global health issues. She also launched the McKinsey Social Initiative (now McKinsey.org), a nonprofit that builds partnerships for social impact. She is a member of the Council on Foreign Relations, the American Public Health Association, the National Academy of Medicine, the National Medical Association and the American Academy of Pediatrics. Named one of Forbes' "100 Most Powerful Women" and one of NonProfit Times' "Power and Influence Top 50," she has authored numerous articles on global and domestic public health issues, poverty alleviation, gender equality and social justice. Dr. Gayle was born and raised in Buffalo, NY. She earned a BA in psychology at Barnard College, an MD at the University of Pennsylvania, and an MPH at Johns Hopkins University. She has received 18 honorary degrees and holds faculty appointments at the University of Washington and Emory University.

PARTICIPANTS



Anne Heatherington, PhD

Anne Heatherington is Senior Vice President and Head of Data Sciences Institute (DSI) with Research and Development (R&D) at Takeda Pharmaceuticals. In this role, she oversees many of the quantitative groups within Takeda, including Statistics and Quantitative Solutions, Global Evidence and Outcomes, Quantitative Clinical Pharmacology, Data Architecture, and Digital Solutions and Digital Strategy Group. Her mandate is to drive innovation and excellence in R&D through focusing on knowledge through data, enabling patient-centricity and developing tools and infrastructure to thoroughly understand the safety and efficacy of Takeda's medicines. Anne has over 20 years experience leading organizations and programs in large pharma, mid-size biotechs, and start-up organizations, including Summit Therapeutics, Pfizer Ltd, and Amgen Inc. Anne received her bachelor's degree in pharmacy from Queen's University Belfast, Northern Ireland, and her PhD in pharmacokinetics from the University of Manchester, England. She completed post-doctoral training in the Centre for Bioengineering at University of Washington, Seattle.

Sandra J. Horning, MD

Sandra J. Horning, MD, FACP, FASCO, is a Board Member of Gilead Sciences and of Moderna. Previously, Dr. Horning was Chief Medical Officer and Head of Global Product Development for Roche/Genentech. She led employees in the Product Development organization across the globe and oversaw all aspects of late stage clinical development. During her tenure, she received recognition for her industry contributions and oversaw the successful development of 14 new molecular entities and numerous line extension in oncology, hematology, neuroscience, ophthalmology, immunology, and infectious disease. Sandra joined Roche in late 2009 as Senior Vice President, Global Head of Clinical Science/Oncology and Hematology in the Product Development organization. Prior to that, she served as a tenured Professor, practicing oncologist and investigator, and held multiple leadership positions including Vice-Chair of the Department of Medicine at Stanford University, where she is an Emerita Professor of Medicine (Oncology and Blood and Bone Marrow Transplantation). Sandra has authored more than 300 peer-reviewed journal articles, book chapters, reviews, and editorials, and has served on the editorial boards of multiple peer-reviewed medical journals. She was named a Best Doctor in America consecutively from 1992-2008 and served as Chairman of the Eastern Cooperative Oncology Group lymphoma committee and as the 2005-2006 President of the American Society of Clinical Oncology. Sandra received Bachelor of Arts and Doctor of Medicine degrees at the University of Iowa and completed post-doctoral training in internal medicine at the University of Rochester and in medical oncology at Stanford University.

Thomas Hudson, MD

Thomas Hudson, MD, Senior Vice President, R&D and CSO, AbbVie, leads the company's R&D organization and a global team of scientists who work across therapeutic areas to identify potential new treatments for a variety of diseases. Dr. Hudson leads R&D strategy for the company as well as providing leadership for the many scientific partnerships AbbVie pursues. Dr. Hudson joined AbbVie in 2016, overseeing oncology discovery and early development before assuming responsibilities for the entire discovery organization as Vice President, Discovery. Prior to joining AbbVie, Dr. Hudson was the President and Scientific Director of the Ontario Institute for Cancer Research where he led the institute's work in translational research for the prevention, detection, diagnosis and treatment of cancer. A Canadian genome scientist, Dr. Hudson was a pioneer in mapping the human genome and is internationally renowned for his work in genomics, human genome variation and genetic diseases. Dr. Hudson has co-authored more than 300 peer-reviewed scientific publications.

PARTICIPANTS

Mir Imran, MS

Mir Imran is the Chairman and CEO of Rani Therapeutics, the leader in oral biologics delivery. The company has demonstrated bioavailability similar to subcutaneous injections in both preclinical and clinical studies with the RaniPill™. After attending medical school, Mir began his career as a healthcare entrepreneur in the late 1970s and has founded more than 20 life sciences companies since those early days, more than half of which have been acquired. Mr. Imran's passion is creating novel technologies that have the potential to positively impact the lives of millions of patients, and he has become one of the leading inventors and entrepreneurs in the field. Mr. Imran holds more than 500 issued and pending patents and is perhaps most well-known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator (ICD).



Kathrin Jansen, PhD

Kathrin U. Jansen, PhD, is the Senior Vice President and Head of Vaccine Research and Development (VRD) at Pfizer Inc, and a member of Pfizer's Worldwide Research, Development and Medical leadership team. With over 28 years of pharmaceutical experience in Vaccine R&D. Dr. Jansen leads a fully integrated, global vaccines research and development organization, with responsibilities ranging from discovery to registration and post-marketing commitments. She manages a clinical vaccines portfolio that includes vaccines to prevent or treat diseases of significant unmet medical need such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Streptococcus pneumoniae, Clostridioides difficile, Respiratory syncytial virus, Group B streptococcus, and Lyme disease. In collaboration with BioNTech, Dr. Jansen led the development of the BNT162b2 vaccine candidate against coronavirus disease 2019 (Covid-19). The vaccine was issued the first emergency use authorization (EUA) by the U.S. Food and Drug Administration – less than 11 months after the SARS-CoV-2 genetic sequence was released and the first-ever authorized vaccine utilizing an mRNA platform. Before the Wyeth acquisition by Pfizer in 2009, Dr. Jansen served as Senior Vice President at Wyeth Pharmaceuticals and on Wyeth's R&D Executive Committee since 2006 and was responsible for vaccine discovery, early development, and clinical testing operations. Dr. Jansen spent 12 years at Merck Research Laboratories. Dr. Jansen initiated R&D activities and led the research and development activities of Gardasil®, the world's first cervical cancer vaccine. Dr. Jansen received her doctoral degree in microbiology, biochemistry & genetics from Phillips Universitaet, Marburg, Germany, in 1984. Following completion of her formal training, she continued her postdoctoral training at Cornell University. She then joined the Glaxo Institute for Molecular Biology in Geneva, Switzerland.

PARTICIPANTS

Peter S. Kim, PhD

Peter S. Kim is the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine and an Institute Scholar of Stanford ChEM-H. He is also the Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub. He was President of Merck Research Laboratories from 2003–2013 and oversaw development of more than 20 new medicines and vaccines, including JANUVIA, the first DPP-4 inhibitor for type 2 diabetes; GARDASIL, the first vaccine for the prevention of cervical cancer; ISENTRESS, the first HIV-1 integrase inhibitor; ZOSTAVAX, the first vaccine for the prevention of shingles; and KEYTRUDA, the first FDA approved PD-1 immune checkpoint inhibitor for the treatment of cancer. Earlier, he was Professor of Biology at MIT, Member of the Whitehead Institute and an HHMI Investigator, where he discovered a salient component of how proteins cause viral membranes to fuse with cells, designed novel compounds to stop membrane fusion by HIV-1, and pioneered efforts to create an AIDS vaccine based on similar principles. His current service includes the Medical Advisory Board of the Howard Hughes Medical Institute (HHMI); the Scientific Advisory Board of the NIH Vaccine Research Center; and the Biology Department Visiting Committee of the MIT Corporation. He is a member of the National Academy of Sciences, the National Academy of Medicine and the National Academy of Engineering.

Nina Kjellson

Nina Kjellson has been a General Partner at Canaan since 2015 and invests in biopharma and digital health start-ups that serve high unmet needs. She has 20 years of experience funding, growing, and transacting early-stage companies. Current Canaan investments include Intrepida, Pact Pharma, Tizona, Tyra, and Vineti. She also serves on the board of WellTok and previously served on the boards of Labrys (acquired by Teva), Cidara (CDTX), Trius (TSX, acquired by Cubist), Eiger (EIGR), NovaCardia (acquired by Merck), and co-sponsored investments into Paratek (PRTK), Tesaro (TSRO, acquired by GSK), and Aspreva (ASPV, acquired by Galenia), along with numerous other ventures during her tenure at InterWest Partners. As a leader of Canaan's Women of Venture program, Nina is a vocal advocate for female entrepreneurs and investors. She serves as an advisor to Springboard Life Sciences, Nina Capital (no relation), The Gates Foundation, and serves on the boards of Essential Access Health, Girl Effect, and the Oliver Wyman Health Innovation Center. Nina is a 2018 Aspen Institute Health Innovators Fellow. Prior to InterWest and Canaan, Nina worked at Bay City Capital, Oracle Partners and the Kaiser Family Foundation. She holds a BA in human biology from Stanford University. Nina is an avid reader, is active in nature, runs, skis and loves to travel the world.

PARTICIPANTS

Brian Kobilka, MD

Brian Kobilka, MD, is Professor of Molecular and Cellular Physiology, and Hélène Irwin Fagan Chair in Cardiology at Stanford University School of Medicine. He received a Bachelor of Science Degrees in Biology and Chemistry from the University of Minnesota, Duluth in 1977. He graduated from Yale University School of Medicine in 1981, and completed residency training in Internal Medicine at the Barnes Hospital, Washington University School of Medicine, St. Louis, Missouri in 1984. From 1984-1989 he was a postdoctoral fellow in the laboratory of Robert Lefkowitz at Duke University. In 1990 he joined the faculty of Medicine and Molecular and Cellular Physiology at Stanford University. Research in the Kobilka lab focuses on the structure and mechanism of action of G protein coupled receptors (GPCRs), which constitute the largest family of receptors for hormones and neurotransmitters in the human genome. GPCRs are the largest group of targets for new therapeutics for a very broad spectrum of diseases. In 2012, Dr. Kobilka was awarded the Nobel Prize in Chemistry for his work on GPCRs. He is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences.

Roger Kornberg, PhD

Roger Kornberg is Winzer Professor in Medicine and Professor of Structural Biology at Stanford University. He received a bachelor's degree in chemistry from Harvard College in 1967 and a PhD in chemistry from Stanford in 1972. His first research was on the dynamics of lipid bilayers. He used nuclear and electron paramagnetic resonance to determine the rates of diffusional motions of lipids, termed flip-flop and lateral diffusion. He then turned to X-ray diffraction of chromatin and, in 1974, proposed the existence and structure of the nucleosome. This proposal was borne out in detail by subsequent structural studies. Dr. Kornberg moved to his present position in 1978, where his research has focused on the mechanism and regulation of eukaryotic gene transcription. Results of this research include the near atomic structure of RNA polymerase II, the elucidation of the RNA polymerase II transcription machinery, and the discovery of the Mediator of transcriptional regulation. Parallel studies of metal clusters have included atomic structures large gold nanoparticles by X-ray crystallography and aberration-corrected electron microscopy. Kornberg has received many awards, including the Welch Prize (2001), highest award in chemistry in the United States, the Leopold Mayer Prize (2002), highest award in biomedical sciences of the French Academy of Sciences, and the Nobel Prize in Chemistry (unshared, 2006). He is a member of National Academies in the US and Europe and a recipient of honorary degrees from universities in Europe and Israel. His longest and closest collaborator has been his wife, Professor Yahli Lorch. They have three children, Guy, Maya, and Gil.

PARTICIPANTS

Nanna Lüneborg, PhD

Dr. Lüneborg joined Novo Holdings in 2012, and spent four years with the Novo Seeds team, where she helped build a portfolio of seed and Series A stage companies, primarily in Scandinavia. She led the initial investments and served on the Boards of IO Biotech, MinervaX, Inthera, and Glionova, and as an Observer with Forendo and Galecto. She joined the Ventures team in 2016, and currently serves on the Boards of Lava, NodThera, Reviral, and Stargazer. Previous investments and board roles include NBE Therapeutics (acquired by Boehringer Ingelheim), Inventiva (IVA), Orphazyme (ORPHA), and ObsEva (OBSV). From 2008-2012, Nanna was an Associate with Apposite Capital, a London-based venture fund, where she was part of the life science investment team and participated in both primary and secondary investments, with multiple portfolio companies leading to highly successful exits for the fund. Earlier in her career, she worked at Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA. Nanna received her PhD in Neuroscience from University College London as a Wellcome Trust Scholar. She holds an MBA with distinction from University of Cambridge, where she was a Sainsbury Scholar, and a 1st class BA from University of Oxford.

Yvonne Maldonado, MD

Dr. Maldonado is the Senior Associate Dean, Faculty Development and Diversity, Taube Professor of GlobalHealth and Infectious Diseases, Professor of Pediatrics (Infectious Diseases) and of Epidemiology and Population Health. Her research has been focused on epidemiologic aspects of viral vaccine development and prevention of perinatal HIV transmission. A major project has been to identify the molecular epidemiology of factors affecting the immunogenicity of oral polio vaccine (OPV) among children living in developing areas ofthe world, where OPV immunogenicity is poor. Her team has identified several factors which affect the poor immunogenicity of OPV and will conduct clinical studies toattempt to improve immunogenicity. She is working on ways to understand the transmission and circulation of polio vaccine derived viruses, which may cause polio, and how to use this information in global eradication of polio. Dr. Maldonado also works on perinatal HIV infection, including strategies to prevent breastfeeding transmission indeveloping settings as well as understanding how to maximize prevention strategies among pregnant women in developed countries.

Fady Malik, MD, PhD

Fady I. Malik, MD, PhD, is the Executive Vice President of Research and Development at Cytokinetics, a biotechnology company based in South San Francisco. Dr. Malik has been with Cytokinetics since its inception in 1998 in a variety of roles, including Vice President, Biology and Therapeutics, all focused towards building the company's cardiovascular and muscle therapeutic programs. Since 2000, Dr. Malik has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently a Clinical Professor of Medicine and formerly was an Attending Interventional Cardiologist at the San Francisco Veterans Administration and UCSF Medical Centers. Dr. Malik received a BS in bioengineering from the University of California at Berkeley, and a MD/PhD from the University of California at San Francisco where he also completed an internal medicine residency and fellowship in cardiology.

PARTICIPANTS

Mathai Mammen, MD, PhD

As Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, Dr. Mammen's mission is to focus the energy of the best research and development teams in the world at the intersection of profound unmet medical need and actionable breakthroughs in science and technology to make medicines of unequivocal benefit for humanity. The team works across a wide range of therapeutic areas and biological pathways. Janssen's approach to medicines is patient-focused, agnostic to both source of the idea and the treatment modality. The team is invested deeply in data sciences in every aspect of R&D. Janssen R&D has fueled the growth of Janssen to be the largest pharmaceutical company in the United States, and the fourth largest in the world. Prior to Janssen, Dr. Mammen was Senior Vice President at Merck Research Laboratories, and with his team initiated numerous new programs and progressed eight into early clinical development. At Theravance, a company he co-founded in 1997, his talented team nominated 31 development candidates in 17 years, created 4 approved products, and filed for a fifth. Dr. Mammen has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his MD from Harvard Medical School/Massachusetts Institute of Technology and his PhD in Chemistry from Harvard.

Joan Mannick, MD

Dr. Mannick is Head of Research and Development at Life Biosciences. Prior to joining Life Bioscience, she was the Chief Medical Officer of resTORbio, a clinical stage biotechnology company that is a spin-out of Novartis and developing medicines that target the biology of aging to treat or prevent aging-related diseases. Prior to joining resTORbio, Dr. Mannick was an Executive Director in the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research. Prior to joining Novartis in 2010, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas. Prior to Genzyme, Dr. Mannick was a faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology. Dr. Mannick received her AB from Harvard College and her MD from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women's Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program. She is board-certified in Internal Medicine and Infectious Diseases.

Ken Mills

Ken Mills is the founding President and Chief Executive Officer of REGENXBIO. Prior to REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company's operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an SB in chemistry from the Massachusetts Institute of Technology.

Lloyd B. Minor, MD

Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since December 2012. He is also a professor of Otolaryngology – Head and Neck Surgery and a Professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University. As Dean, Dr. Minor plays an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Children's Health and Lucile Packard Children's Hospital Stanford. He also oversees the quality of Stanford Medicine's physician practices and growing clinical networks. With Dr. Minor's leadership, Stanford Medicine has established a strategic vision to lead the biomedical revolution in Precision Health. The next generation of health care, Precision Health, is focused on keeping people healthy and providing care that is tailored to individual variations. It is predictive, proactive, preemptive, personalized, and patient-centered. An advocate for innovation, Dr. Minor has provided significant support for fundamental science and for clinical and translational research at Stanford. Through bold initiatives in medical education and increased support for PhD students, Dr. Minor is committed to inspiring and training future leaders. Among other accomplishments Dr. Minor has led the development and implementation of an innovative model for cancer research and patient care delivery at Stanford Medicine and has launched an initiative in biomedical data science to harness the power of big data and create a learning health care system. Committed to diversity, he has increased student financial aid and expanded faculty leadership opportunities.

Woodrow Myers, Jr., MD, MBA

Woodrow Myers, Jr., MD, MBA, is a nationally recognized leader in the development of medical quality initiatives and advanced healthcare management programs. As Managing Director of Myers Ventures LLC, he has coupled his passion for the highest standards of patient care and management, with leadership roles in several of our largest and most innovative healthcare enterprises. Through Myers Ventures LLC, Dr. Myers has served as Chief Medical Officer and Chief Healthcare Strategist for Blue Cross Blue Shield of Arizona, CEO for Valitàs Health Services (Corizon Health), and as consultant to the California Endowment. He has served on multiple public, private, and nonprofit boards including Express Scripts, Genomic Health, LipoScience, and SynGen. In higher education, he served on the Board of Trustees of Stanford University, Board of Overseers of Harvard University, and the Board of Trustees of the Charles R. Drew University of Medicine and Science. From July 2019 – November 2020, Dr. Myers was the Democratic candidate for Governor of Indiana, and in 2008 Dr. Myers was a candidate in the Democratic primary election in the Indiana 7th Congressional district. He is the former Executive Vice President and Chief Medical Officer of WellPoint, Inc., where he established the Healthcare Quality Assurance Division. He is a former health commissioner for the city of New York and the state of Indiana. He is deeply committed to improving the quality, availability, and efficiency of healthcare around the globe. He is passionate about innovation and technology improvements that will improve healthcare delivery and human longevity. Dr. Myers received his BS at Stanford University, his MD from Harvard Medical School, and his MBA from Stanford University Graduate School of Business.

PARTICIPANTS



Michael Nedelman

Michael Nedelman covers health and medicine for CNN. Previously, he was a digital producer for ABC News' Medical Unit, worked on public health campaigns at the World Health Organization in New Delhi, and trained at the Stanford Journalism Program as part of Stanford's Global Health Media Fellowship while in medical school. He holds a degree in Film Studies from Yale.



Julie Parsonnet, MD

Dr. Parsonnet is the George deForest Barnett Professor in Medicine and Professor of Epidemiology and Population Health. She specializes in adult infectious diseases. She has a particular interest in gastrointestinal infections, including H. pylori infection and diarrheal diseases, tuberculosis, and illnesses with prolonged fever. Dr. Parsonnet also has an active research enterprise in which she studies the way infections contribute to the development of chronic diseases including cancer, allergy, and obesity. She has had continuous funding from the National Institutes of Health for over 25 years and has served as a member of numerous advisory boards, professional societies, and scientific review committees.

Philip A. Pizzo, MD

Philip Pizzo, MD, is the David and Susan Heckerman Professor and Founding Director of the Stanford Distinguished Careers Institute. Dr. Pizzo served as Dean of the Stanford School of Medicine from April 2001 to December 1, 2012, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Dr. Pizzo has devoted much of his distinguished medical career to the diagnosis, management, prevention, and treatment of childhood cancers and the infectious complications that occur in children whose immune systems are compromised by cancer and AIDS. He has also been a leader in academic medicine, championing programs and policies to improve the future of science, education, and healthcare in the US and beyond. Dr. Pizzo received his MD degree with Honors and Distinction in Research from the University of Rochester in 1970, and completed an internship and residency at Children's Hospital Medical Center in Boston, a teaching fellowship at Harvard Medical School, and a clinical and research fellowship in pediatric oncology at the National Cancer Institute. Pizzo served as Head of the Institute's infectious disease section, Chief of the NCI's Pediatric Department, and Acting Scientific Director for NCI's Division of Clinical Sciences between 1973 and 1996. Before joining Stanford in 2001, he was the physician-in-chief of Children's Hospital in Boston and Chair of the Department of Pediatrics at Harvard Medical School, where he was also the Thomas Morgan Rotch Professor of Pediatrics. He has been elected to a number of prestigious organizations and societies, including the Association of American Physicians, the American Society of Clinical Investigation, the American Pediatric Society, and the Institute of Medicine of the National Academy of Sciences, where he was also elected to the Governing Council.

PARTICIPANTS

Andrew Plump, MD, PhD

Andrew Plump, MD, PhD, is the President, Research & Development of Takeda Pharmaceutical Company Limited and serves as a member of the company's Board of Directors. His career spans nearly 30 years in the pharmaceutical industry and academia and his experience encompasses early research through regulatory approval and patient access. Dr. Plump's approach toward drug research and development is reflected in a virtuous cycle of "bench to bedside to bench" learning. He is a true translational physician-scientist, with deep knowledge in biomedical research, experimental medicine, early development, genomics, and biomarkers and a history of scientific contributions in neuroscience, cardiovascular, and metabolic diseases. Throughout his career, Dr. Plump has been motivated to make an impact for patients by translating groundbreaking science into the practice of healthcare. He is regarded as a multi-dimensional leader who is passionate about leading diverse, cross-functional teams and nurturing a high-performing culture to achieve a shared mission, innovate for patients and change health for the better. Currently, Dr. Plump leads Takeda's modern, world-class, global R&D organization of ~5,000 employees. Prior to Takeda, Dr. Plump served as Senior Vice President, Research & Translational Medicine, Deputy to the President of R&D at Sanofi, based in Paris, France. Prior to Sanofi, Dr. Plump served as Vice President, Worldwide Cardiovascular (CV) Research Head at Merck, where he had direct responsibility for CV research, preclinical development and translational sciences.

Camille Samuels, MBA

Camille Samuels, MBA, is a Partner at Venrock, a venture capital firm originally established in the late 1960s as the venture arm of the Rockefeller family. Her investment interests span early-stage biotech to medical devices to consumer health. She serves on the board of directors of Unity biotech (UBX), a public longevity company — and is an observer on the board at Corvidia, a private cardiorenal company. She stepped off the board of RegenXBIO (RGNX) a year after it went public — and from Spirox after its acquisition by Entellus (and Stryker). Prior to Venrock, Cami spent over a decade as a Managing Director at Versant Ventures, a leading life sciences venture capital firm. While at Versant, Cami seeded Kythera (makers of Kybella) and served on the company's board through its IPO and eventual sale to Allergan for $2.1B. In addition, she served as a board member or a board observer on many other innovative healthcare companies including: Achaogen (AKAO), Carmenta (acquired by Progenity), Fluidigm (FLDM), Genomic Health (GHDX), Novacardia (acquired by Merck), ParAllele (acquired by Affymetrix), and Syrrx (acquired by Takeda).

Serge Saxonov, PhD

Serge Saxonov co-founded 10x Genomics in 2012. As the CEO, he defined the 10x Genomics vision and strategy, contributed to core inventions, and has led the company since inception. Prior to 10x Genomics, Serge was Vice President of Applications at QuantaLife, where he built products and defined the company's growth areas. Dr. Saxonov was the first employee at 23andMe, where he served as Founding Architect and Director of R&D. There he defined the initial concept of the product, built out the core technology, and drove strategy and execution of R&D functions. Serge received a PhD in biomedical informatics from Stanford University and an AB in applied mathematics from Harvard College.

Marcus Schindler, PhD

Marcus Schindler, PhD, Prof., is Executive Vice President and CSO, Research & Early Development at Novo Nordisk A/S. Marcus joined Novo Nordisk in 2018 as SVP for External Innovation & Strategy before he was appointed to lead Global Drug Discovery. Over the last 3 years he has led the transformation of drug discovery towards novel therapy areas such as Cardiovascular (CV) and Non-Alcoholic Steatohepatitis (NASH), human centric approaches, a portfolio of projects with new modes of action, and the implementation of novel treatment modalities such as stem cells and siRNA. The organization also opened to more external innovation and diversity of approach with a significant increase in partnerships, the establishment of an Innovation Hub in Boston and Transformational Research Units (TRU). Since March 1, 2021, he leads the newly created EVP area Research and Early Development (R&ED) with accountability for driving scientific innovation to human proof-of-mechanism. He also represents Novo Nordisk as Supervisory Board Member of Innate Pharma (France) and is Adjunct Professor of Pharmacology at the University of Gothenburg (Sweden). Marcus has close to 20 years of experience in leadership roles in the pharmaceutical industry, working both in international large pharma and biotechnology companies including AstraZeneca (Sweden), Boehringer Ingelheim (Germany) and (OSI)Prosidion (UK). Marcus Schindler received his PhD in Pharmacology from the University of Cambridge. He as co-/authored 50+ peer-reviewed research papers and is an inventor of 25 international patent applications.

Mark Smith, MD, MBA

Dr. Smith is currently a Professor of Clinical Medicine at the University of California at San Francisco. From 2016 through 2019 he co-chaired the Guiding Committee of the Health Care Payment Learning and Action Network. From 1996 through 2013, Smith was the Founding President of the California HealthCare Foundation, which he led from its formation. An independent endowed philanthropy in Oakland, CA, the Foundation began operations with $500 million in assets, made $650 million in charitable grants under his leadership, and has a current corpus of approximately $720 million. In those 17 years, Smith helped build the Foundation into a recognized leader in delivery system innovation, public reporting of quality, and applications of new technology in health care. Smith spearheaded the launch of California HealthLine; and the CHCF Innovation Fund, which invests in companies advancing the Foundation's mission; and the CHCF Leadership Fellows Program, whose 300 alumni/ae are senior leaders in virtually every clinical enterprise in the state. He was a 2014 Menschel Senior Policy Fellow at the Harvard School of Public Health. Smith is a nationally recognized health policy expert. Before his time at CHCF, Dr. Smith was Executive Vice President of the Henry J. Kaiser Family Foundation, where he oversaw programs in HIV, Reproductive Health, and the Health Care Marketplace. Prior to that, he was on the faculty at the Johns Hopkins Schools of Medicine and of Public Health and directed the AIDS clinic there. Dr. Smith was elected to the Institute of Medicine (IOM) in 2001. He chaired the IOM's Committee on the Learning Healthcare System, which produced the widely publicized 2012 report Best Care at Lower Cost. He serves on the Boards of the Institute for Healthcare Improvement, the Commonwealth Fund, Teladoc Health, Phreesia Inc., Jazz Pharmaceuticals, and the Editorial Board of Health Affairs. Dr. Smith holds a BA in Afro-American Studies from Harvard College, an MD from the University of North Carolina at Chapel Hill, and an MBA from the Wharton School at the University of Pennsylvania. A Board-certified internist, he maintains an active clinical practice in HIV care at San Francisco General Hospital.

PARTICIPANTS

Orla Smith, PhD

Orla Smith, PhD, is the Editor of *Science Translational Medicine*, an international weekly online publication of the American Association for the Advancement of Science (AAAS), and a sister journal of *Science* magazine. *Science Translational Medicine* publishes cutting-edge biomedical and translational research advances with clinical impact, as well as review and opinion articles by thought leaders that discuss key issues about translational medicine. The Impact Factor for *Science Translational Medicine* is 16.3. Previously, Orla was the Founding Editor of *Cell*'s Leading Edge, the review and opinion section of the top-ranked research journal *Cell*, based in Boston, U.S. Prior to her time at *Cell*, Orla was Biology Perspectives Editor at *Science* where she also handled and edited research manuscripts on neurodegenerative diseases. She began her career in scientific publishing as News and Views Editor at the journal *Nature Medicine*. Orla has a PhD in Biochemistry from the Royal Free Hospital School of Medicine, University of London.

Young Sohn, MS

Young Sohn is a Silicon Valley entrepreneur whose passion is building businesses and fostering emerging technologies that have the potential to transform the world for the better. Currently, Mr. Sohn serves as Chairman of the Board of HARMAN and Senior Advisor to Samsung Electronics. Recently, Mr. Sohn served as Corporate President and Chief Strategy Officer of Samsung Electronics, where he led strategy for global innovation, investment, new business creation, and led the company's $8 billion acquisition of HARMAN International. Prior to joining Samsung Electronics, Mr. Sohn served as CEO of two successful, public Silicon Valley companies and on the boards of Arm, Cymer (ASML), and others. Under his leadership as CEO and board member, he took PLX Technologies, Synnex Technologies, and Inphi public. He was also a seed investor in some of the industry's most innovative companies including Fungible, Graphcore, and Zoom. Mr. Sohn co-founded the Extreme Tech Challenge (XTC), the world's largest startup competition for entrepreneurs addressing global challenges. He also serves as a senior advisor to the private equity firm Silver Lake Partners, is a member of the Board of Directors at Cadence, is a board member of the Global Semiconductor Alliance (GSA), and is an advisor for the University of California Innovation Council. Sohn holds a BS in electrical engineering from the University of Pennsylvania and MS from the MIT Sloan School of Management. An avid outdoorsman, Sohn spends his personal time kite surfing, competing in triathlons, and hiking.

Marc Tessier-Lavigne, PhD

Pioneering neuroscientist Marc Tessier-Lavigne became Stanford University's 11th president on September 1, 2016. He returned to Stanford after serving as President of The Rockefeller University, a graduate biomedical research university in New York City. From 2001 to 2005, he was a Professor of biological sciences at Stanford, where he held the Susan B. Ford Professorship in the Humanities and Sciences. He has also held faculty positions at the University of California, San Francisco, and executive positions, including Chief Scientific Officer at Genentech.

Janet Woodcock, MD

Janet Woodcock was named Acting Commissioner of Food and Drugs on January 20, 2021. As Acting Commissioner, Dr. Woodcock oversees the full breadth of the FDA portfolio and execution of the Federal Food, Drug, and Cosmetic Act and other applicable laws. This includes assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for human use, and medical devices; the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation; and the regulation of tobacco products. Dr. Woodcock began her FDA career in 1986, joining the agency's Center for Biologics Evaluation and Research (CBER) as Director of the Division of Biological Investigational New Drugs. In 1994, Dr. Woodcock was named Director of the FDA's Center for Drug Evaluation and Research (CDER). In 2004, Dr. Woodcock became Deputy Commissioner and Chief Medical Officer in the Office of the Commissioner. In 2007, Dr. Woodcock returned as Director of CDER until she was asked to lend her expertise to "Operation Warp Speed" for developing therapeutics during the COVID-19 pandemic. From late 2020, she split her time advising "Operation Warp Speed" on advancing COVID-19 therapeutics while also serving as the Principal Medical Advisor to the Commissioner on key priorities on behalf of the Office of the Commissioner. Dr. Woodcock holds a Bachelor of Science in chemistry from Bucknell University (Lewisburg, PA), and a Doctor of Medicine from the Feinberg School of Medicine at Northwestern University Medical School (Chicago). She also completed further training and a fellowship in rheumatology, as well as held teaching appointments at the Pennsylvania State University and the University of California in San Francisco. She is board certified in internal medicine.

George D. Yancopoulos, MD, PhD

George D. Yancopoulos, MD, PhD, is Regeneron's Founding Scientist, President, and Chief Scientific Officer. Dr. Yancopoulos received his MD and PhD from Columbia University and was Dr. Fred Alt's first post-doc, working in molecular immunology. Dr. Yancopoulos pursued a career in academia until he met his Regeneron co-founder, Leonard Schleifer, MD, PhD, in the late 1980s and saw the potential to make a major impact on medicine through biotechnology. Regeneron is now a leading biopharma company with more than 7,000 employees and facilities in the US, Ireland, and the UK. With a robust research and development engine and an unwavering commitment to its science-driven approach, Regeneron has produced seven FDA-approved medicines for patients with serious diseases, including: cancer, vision-threatening eye diseases, atopic dermatitis, and rheumatoid arthritis. Dr. Yancopoulos and his team have built a robust pipeline of investigational treatments, driven by Regeneron's foundational technologies for target discovery and drug development, such as the VelociGene® and VelocImmune® platforms. Regeneron is committed to continual innovations in R&D, such as through the Regeneron Genetics Center, a world-leading human genetics effort that has already sequenced exomes from over 300,000 people. Dr. Yancopoulos is deeply committed to inspiring top talent to pursue scientific careers through STEM education programs. He plays an active role in Regeneron's STEM commitments, including the Regeneron Science Talent Search, the nation's oldest and most prestigious high school science competition, formerly sponsored by Westinghouse and Intel.

Taiyin Yang, PhD

Taiyin Yang is the Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc. Dr. Yang is responsible for all of the company's small molecules, biologics, and antibody-drug conjugates of investigational compounds and marketed products. Under her leadership, Gilead developed the world's first HIV single tablet regimen (Atripla) and advanced more than 25 compounds from early-stage development to market, reaching millions of people around the world. Prior to joining Gilead in 1993, she held leadership positions at Syntex Corporation and contributed to the development and commercialization of more than 10 medicines. Dr. Yang is a member of the Expert Scientific Advisory Committee of Medicines for Malaria Venture, a research and development based non-profit organization for developing antimalarial medicines to save lives. Dr. Yang holds a PhD in organic chemistry from the University of Southern California and a BS degree in chemistry from National Taiwan University.

Wendy Young, PhD

Wendy Young is Senior Vice President of small molecule drug discovery at Genentech. She oversees an organization of 400 scientists in chemistry, drug metabolism, pharmaceutics, and biochemical pharmacology. Dr. Young is a chemist by training and has spent the last 25 years engrossed in the discovery of inhibitors of a variety of protein classes to treat cancer, cardiovascular, and immunology indications. Uunder her leadership, numerous drug candidates have progressed into clinical trials. She was the project team leader and co-inventor of fenebrutinib, a BTK inhibitor, which is currently in Phase II clinical studies in RA, lupus, and urticaria. In 2018, she was awarded the “Genentech Inventor’s Award” for this work. She has authored over 70 research papers and published patent applications. Wendy received a BA/MS degree in 1989 from Wake Forest University, having studied in the labs of Huw M.L. Davies. She then received a PhD in 1993 from Princeton University, under the guidance of Edward C. Taylor. At Princeton, and in collaboration with Eli Lilly, Wendy worked on folate analogs as antitumor agents and Alimta® was an outcome of this collaboration. Thereafter, as an American Cancer Society fellow, she performed post-doctoral studies in the laboratories of Samuel Danishefsky at Sloan-Kettering Cancer Center and was part of the team that completed the total synthesis of Taxol®. Dr. Young is a strong advocate for students and women in STEM careers, and has initiated several programs to support these important under-represented groups. In 2015, Dr. Young was recognized by the San Francisco Business Times as one of San Francisco’s “Most Influential Business Women of 2015.” Wendy has been a longtime supporter of the American Chemical Society, having served many roles on the executive MEDI division and in 2017 was the elected National Chair. In 2018, Wendy was awarded an “ACS Fellows Award” for her lifelong service to chemistry, society, and medicine and in 2019 the ACS National “Earle B. Barnes Award for Leadership in Chemical Research Management” for scientific creativity and dedication to programs and people.



Elias Zerhouni, MD

Dr. Zerhouni was the President, Global Research & Development, and a member of the Executive Committee for Sanofi from January 2011 to July 2018. Dr. Zerhouni's academic career was spent at the Johns Hopkins University and Hospital where he was Professor of Radiology and Biomedical engineering and Senior Adviser for Johns Hopkins Medicine. He served as Chair of the Russell H. Morgan Department of Radiology and Radiological Sciences, Vice Dean for Research and Executive Vice Dean of the School of Medicine from 1996 to 2002 before his appointment as Director of the National Institutes of Health from 2002 to 2008. In 2009, President Obama appointed Dr. Zerhouni as one of the first presidential U.S. science envoys. Dr. Zerhouni also served as senior fellow to the Bill and Melinda Gates Foundation from 2009 to 2010. He authored more than 200 scientific publications and is a member of the U.S. National Academy of Medicine and the U.S. National Academy of Engineering.

ORGANIZING COMMITTEE

Amanda Chase, PhD
Grant Writer and Project Coordinator
Cardiovascular Institute
Stanford University School of Medicine

Sanjay V. Malhotra, PhD, FRSC
Professor & Endowed Chair in Cancer Research
Department of Cell Development & Cancer Biology
Director, Center for Experimental Therapeutics
Knight Cancer Institute
Oregon Health & Science University



Mark Mercola, PhD
Professor of Medicine (Cardiovascular)
Stanford University School of Medicine

Kuldev Singh, MD
Professor of Ophthalmology
Stanford University School of Medicine

Joseph C. Wu MD, PhD
Director, Stanford Cardiovascular Institute
Simon H. Stertzer, MD, Professor of Medicine and Radiology
Stanford University School of Medicine

STAFF SUPPORT

David Preston, MA, MBA
Business Operations and Program Manager

Francesca Tongco
Administrative Associate

SDDS 2021
Stanford Drug Discovery Symposium
April 19-20, 2021

Thank You to our Sponsors

Stanford Cardiovascular Institute

Stanford HEALTH CARE

Stanford Cancer Institute
Stanford MEDICINE

ALEXANDRIA

ALWAYSRAISE

astellas

CODEX DNA

Cytokinetics

Genentech
A Member of the Roche Group

KHLORIS BIOSCIENCES

MERCK

novo nordisk®

SDDS 2021
Stanford Drug Discovery Symposium
April 19-20, 2021

Thank You to our Sponsors

Optina DIAGNOSTICS

REGENXBIO™

Santen

SERVIER

Vala SCIENCES

10X GENOMICS

Media Sponsor Partners:

BIOCOM

CLSA
California Life Sciences Association

KEYSTONE SYMPOSIA

slas
Come Transform Research

Stanford
Cardiovascular Institute
cvi.stanford.edu